ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v21i3.2751ppharm-2464Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWПрименение ингибиторов PD-1 и PD-L1 в детской гематологии: обзор литературыThe administration of PD-1 and PD-L1 inhibitors in pediatric hematology: a literature reviewhttps://orcid.org/0000-0002-3371-8639ПадеринаА. С.PaderinaAleksandra S.

Валиев Тимур Теймуразович - д.м.н.

115478, Москва, Каширское шоссе, д. 24

MD, PhD.

24, Kashirskoe shosse, Moscow, 115478

timurvaliev@mail.ruhttps://orcid.org/0000-0002-1469-2365ВалиевТ. Т.ValievTimur T.

Валиев Тимур Теймуразович - доктор медицинских наук, заведующий детским отделением химиотерапии гемобластозов НИИ ДОиГ им. акад. РАМН Л.А. Дурнова

115478, Москва, Каширское ш., д. 24, тел.: +7 (905) 797-70-06

MD.

Moscow

timurvaliev@mail.ruНМИЦ гематологииРоссияNational Medical Research Center for HematologyRussian FederationНМИЦ онкологии им. Н.Н. БлохинаРоссияN.N. Blokhin National Medical Research Center of OncologyRussian Federation202403072024213240248Copyright © Падерина А.С., Валиев Т.Т., 20242024Падерина А.С., Валиев Т.Т.Paderina A.S., Valiev T.T.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/2464

Открытие иммунных контрольных точек (ИКТ) стало знаковым событием в иммуноонкологии, улучшив понимание механизмов уклонения опухолевых клеток от иммунного надзора. На основании этого была разработана такая группа препаратов, как ингибиторы иммунных контрольных точек (иИКТ), действие которых обусловлено разрывом иммунологического синапса и распознаванием Т-клетками опухоли. В настоящее время иИКТ успешно используются в терапии ряда злокачественных новообразований, улучшив показатели безрецидивной и общей выживаемости. Однако определение роли данных препаратов в лечении детей с опухолями системы крови является предметом активных исследований. В данной статье представлен обзор литературы, посвященный актуальным аспектам применения ингибиторов PD-1 и PD-L1 в детской гематологии. Приведены их механизмы действия, эффективность и потенциальные осложнения терапии.

The discovery of immune checkpoints (IC) has become a landmark event in immuno-oncolog y, improving the understanding of the mechanisms of tumor cells evading immune sur veillance. Based on this, a group of drugs such as immune checkpoint inhibitors (ICIs) were developed, the ef fect of which is due to the rupture of the immunological synapse and recognition by tumor T cells. Currently, ICIs are successfully used in the treatment of a number of malignant neoplasms, improving the indicators of diseasefree and overall sur vival. However, determining the role of these drugs in the treatment of children with tumors of the blood system is the subject of active research. This article presents a review of the literature on topical aspects of the administration of PD-1 and PD-L1 inhibitors in pediatric hematolog y. Their mechanisms of action, ef fectiveness and potential complications of therapy are presented.

ингибиторы иммунных контрольных точекдетигематологияпредикторы эффективностипсевдопрогрессияimmune checkpoint inhibitorschildrenhematologypredictors of effectivenesspseudoprogressionОтсутствуетNot specifiedReferencesKeir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704. https://doi.org/10.1146/annurev.immunol.26.021607.090331Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704. https://doi.org/10.1146/annurev.immunol.26.021607.090331Huang PW, Chang JW. Immune checkpoint inhibitors win the 2018 Nobel Prize. Biomed J. 2019;42(5):299–306. https://doi.org/10.1016/j.bj.2019.09.002Huang PW, Chang JW. Immune checkpoint inhibitors win the 2018 Nobel Prize. Biomed J. 2019;42(5):299–306. https://doi.org/10.1016/j.bj.2019.09.002Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723. https://doi.org/10.1056/NEJMoa1003466Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723. https://doi.org/10.1056/NEJMoa1003466Comin-Anduix B, Escuin-Ordinas H, Ibarrondo FJ. Tremelimumab: research and clinical development. Onco Targets Ther. 2016;9:1767– 1776. doi: https://doi.org/10.2147/OTT.S65802Comin-Anduix B, Escuin-Ordinas H, Ibarrondo FJ. Tremelimumab: research and clinical development. Onco Targets Ther. 2016;9:1767– 1776. doi: https://doi.org/10.2147/OTT.S65802Keam SJ. Tremelimumab: First Approval. Drugs. 2023;83(1):93–102. https://doi.org/10.1007/s40265-022-01827-8Keam SJ. Tremelimumab: First Approval. Drugs. 2023;83(1):93–102. https://doi.org/10.1007/s40265-022-01827-8Larkin J, Chiarion-Sileni V, Gonzalez R, et al.combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. https://doi.org/10.1056/NEJMoa1504030Larkin J, Chiarion-Sileni V, Gonzalez R, et al.combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. https://doi.org/10.1056/NEJMoa1504030Bashey A, Medina B, Corringham S, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009;113(7):1581–1588. https://doi.org/10.1182/blood-2008-07-168468Bashey A, Medina B, Corringham S, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009;113(7):1581–1588. https://doi.org/10.1182/blood-2008-07-168468Davids MS, Kim HT, Bachireddy P, et al. Leukemia and Lymphoma Society Blood Cancer Research Partnership. Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016;375(2):143–153. https://doi.org/10.1056/NEJMoa1601202Davids MS, Kim HT, Bachireddy P, et al. Leukemia and Lymphoma Society Blood Cancer Research Partnership. Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016;375(2):143–153. https://doi.org/10.1056/NEJMoa1601202Zeidan AM, Knaus HA, Robinson TM, et al. A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure. Clin Cancer Res. 2018;24(15):3519–3527. https://doi.org/10.1158/1078-0432.CCR-17-3763Zeidan AM, Knaus HA, Robinson TM, et al. A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure. Clin Cancer Res. 2018;24(15):3519–3527. https://doi.org/10.1158/1078-0432.CCR-17-3763Ansell SM, Hurvitz SA, Koenig PA, et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res, 2009;15(20):6446–6453. https://doi.org/10.1158/1078-0432Ansell SM, Hurvitz SA, Koenig PA, et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res, 2009;15(20):6446–6453. https://doi.org/10.1158/1078-0432Khouri IF, Fernandez Curbelo I, Turturro F, et al. Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. Clin Cancer Res. 2018;24(5):1011–1018. https://doi.org/10.1158/1078-0432.CCR-17-2777Khouri IF, Fernandez Curbelo I, Turturro F, et al. Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. Clin Cancer Res. 2018;24(5):1011–1018. https://doi.org/10.1158/1078-0432.CCR-17-2777Tuscano JM, Maverakis E, Groshen S, et al. A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/ Refractory B-Cell Lymphoma. Clin Cancer Res. 2019;25(23):7004–7013. https://doi.org/10.1158/1078-0432.CCR-19-0438Tuscano JM, Maverakis E, Groshen S, et al. A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/ Refractory B-Cell Lymphoma. Clin Cancer Res. 2019;25(23):7004–7013. https://doi.org/10.1158/1078-0432.CCR-19-0438Armand P, Lesokhin A, Borrello I, et al. A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/ refractory lymphoid Malignancies. Leukemia. 2021;35(3):777–786. https://doi.org/10.1038/s41375-020-0939-1Armand P, Lesokhin A, Borrello I, et al. A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/ refractory lymphoid Malignancies. Leukemia. 2021;35(3):777–786. https://doi.org/10.1038/s41375-020-0939-1Garcia JS, Flamand Y, Penter L, et al. Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplantnaïve settings. Blood. 2023;141(15):1884–1888. https://doi.org/10.1182/blood.2022017686Garcia JS, Flamand Y, Penter L, et al. Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplantnaïve settings. Blood. 2023;141(15):1884–1888. https://doi.org/10.1182/blood.2022017686Diefenbach CS, Hong F, Ambinder RF, et al. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. Lancet Haematol. 2020;7(9):e660–e670. https://doi.org/10.1016/S2352-3026(20)30221-0Diefenbach CS, Hong F, Ambinder RF, et al. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. Lancet Haematol. 2020;7(9):e660–e670. https://doi.org/10.1016/S2352-3026(20)30221-0Qin S, Xu L, Yi M, et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155. https://doi.org/10.1186/s12943-019-1091-2Qin S, Xu L, Yi M, et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155. https://doi.org/10.1186/s12943-019-1091-2Wu X, Gu Z, Chen Y, et al. Application of PD-1 Blockade in Cancer Immunotherapy.comput Struct Biotechnol J. 2019;17:661–674. https://doi.org/10.1016/j.csbj.2019.03.006Wu X, Gu Z, Chen Y, et al. Application of PD-1 Blockade in Cancer Immunotherapy.comput Struct Biotechnol J. 2019;17:661–674. https://doi.org/10.1016/j.csbj.2019.03.006Bardhan K, Anagnostou T, Boussiotis VA. The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Front Immunol. 2016;7:550. https://doi.org/10.3389/fimmu.2016.00550Bardhan K, Anagnostou T, Boussiotis VA. The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Front Immunol. 2016;7:550. https://doi.org/10.3389/fimmu.2016.00550Tinoco R, Carrette F, Barraza ML, et al. PSGL-1 Is an Immune Checkpoint Regulator That Promotes T Cell Exhaustion. Immunity. 2016;44:1190–1203. https://doi.org/10.1016/j.immuni.2016.04.015Tinoco R, Carrette F, Barraza ML, et al. PSGL-1 Is an Immune Checkpoint Regulator That Promotes T Cell Exhaustion. Immunity. 2016;44:1190–1203. https://doi.org/10.1016/j.immuni.2016.04.015Li F, Li C, Cai X, et al. The association between CD8+ tumorinfiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis. eClinicalMedicine. 2021;41:101134. https://doi.org/10.1016/j.eclinm.2021.101134Li F, Li C, Cai X, et al. The association between CD8+ tumorinfiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis. eClinicalMedicine. 2021;41:101134. https://doi.org/10.1016/j.eclinm.2021.101134Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268–3277. https://doi.org/10.1182/blood-2010-05-282780Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268–3277. https://doi.org/10.1182/blood-2010-05-282780Mottok A, Hung SS, Chavez EA, et al. Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. Blood. 2019;134(10):802–813. https://doi.org/10.1182/blood.2019001126Mottok A, Hung SS, Chavez EA, et al. Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. Blood. 2019;134(10):802–813. https://doi.org/10.1182/blood.2019001126Chapuy B, Roemer MGM, Stewart C, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127(7):869–881. https://doi.org/10.1182/blood-2015-10-673236Chapuy B, Roemer MGM, Stewart C, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127(7):869–881. https://doi.org/10.1182/blood-2015-10-673236Song TL, Nairismägi M-L, Laurensia Y, et al. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. Blood. 2018;132(11):1146–1158. https://doi.org/10.1182/blood-2018-01-829424Song TL, Nairismägi M-L, Laurensia Y, et al. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. Blood. 2018;132(11):1146–1158. https://doi.org/10.1182/blood-2018-01-829424Liao D, Wang M, Liao Y, et al. A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia. Front Pharmacol. 2019;10:609. https://doi.org/10.3389/fphar.2019.00609Liao D, Wang M, Liao Y, et al. A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia. Front Pharmacol. 2019;10:609. https://doi.org/10.3389/fphar.2019.00609Zhao S, Zhang M, Zhang Y, et al. The prognostic value of programmed cell death ligand 1 expression in non-Hodgkin lymphoma: A meta-analysis. Cancer Biol Med. 2018;15(3):290. https://doi.org/10.20892/j.issn.2095-3941.2018.0047Zhao S, Zhang M, Zhang Y, et al. The prognostic value of programmed cell death ligand 1 expression in non-Hodgkin lymphoma: A meta-analysis. Cancer Biol Med. 2018;15(3):290. https://doi.org/10.20892/j.issn.2095-3941.2018.0047Qiu L, Zheng H, Zhao X. The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: A meta-analysis. BMC Cancer. 2019;19(1):273. https://doi.org/10.1186/s12885-019-5466-yQiu L, Zheng H, Zhao X. The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: A meta-analysis. BMC Cancer. 2019;19(1):273. https://doi.org/10.1186/s12885-019-5466-yGaron EB, Rizvi NA, Hui R, et al. KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–2028. https://doi.org/10.1056/NEJMoa1501824Garon EB, Rizvi NA, Hui R, et al. KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–2028. https://doi.org/10.1056/NEJMoa1501824Dilly-Feldis M, Aladjidi N, Refait JK, et al. Expression of PD-1/ PD-L1 in children’s classical Hodgkin lymphomas. Pediatr Blood Cancer. 2019;66(5):e27571. https://doi.org/10.1002/pbc.27571Dilly-Feldis M, Aladjidi N, Refait JK, et al. Expression of PD-1/ PD-L1 in children’s classical Hodgkin lymphomas. Pediatr Blood Cancer. 2019;66(5):e27571. https://doi.org/10.1002/pbc.27571Fisher KE, Ferguson LS, Coffey AM, et al. Programmed cell death ligand 1 expression in aggressive pediatric non-Hodgkin lymphomas: frequency, genetic mechanisms, and clinical significance. Haematologica. 2022;107(8):1880–1890. https://doi.org/10.3324/haematol.2021.280342Fisher KE, Ferguson LS, Coffey AM, et al. Programmed cell death ligand 1 expression in aggressive pediatric non-Hodgkin lymphomas: frequency, genetic mechanisms, and clinical significance. Haematologica. 2022;107(8):1880–1890. https://doi.org/10.3324/haematol.2021.280342Majzner RG, Simon JS, Grosso JF, et al. Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues. Cancer. 2017;123(19):3807-3815. https://doi.org/10.1002/cncr.30724Majzner RG, Simon JS, Grosso JF, et al. Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues. Cancer. 2017;123(19):3807-3815. https://doi.org/10.1002/cncr.30724Autio M, Leivonen S-K, Brück O, et al. Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma. Haematologica. 2020;106(3):718–729. doi:https://doi.org/10.3324/haematol.2019.243626Autio M, Leivonen S-K, Brück O, et al. Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma. Haematologica. 2020;106(3):718–729. doi:https://doi.org/10.3324/haematol.2019.243626Leivonen S-K, Pollari M, Brück O, et al. T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma. Haematologica. 2019;104(2):338–346. https://doi.org/10.3324/haematol.2018.200105Leivonen S-K, Pollari M, Brück O, et al. T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma. Haematologica. 2019;104(2):338–346. https://doi.org/10.3324/haematol.2018.200105Wu H, Tang X, Kim HJ, et al. Expression of KLRG1 and CD127 defines distinct CD8+ subsets that differentially impact patient outcome in follicular lymphoma. J Immunother Cancer. 2021;9(7):e002662. https://doi.org/10.1136/jitc-2021-002662Wu H, Tang X, Kim HJ, et al. Expression of KLRG1 and CD127 defines distinct CD8+ subsets that differentially impact patient outcome in follicular lymphoma. J Immunother Cancer. 2021;9(7):e002662. https://doi.org/10.1136/jitc-2021-002662Nygren L, Wasik AM, Baumgartner-Wennerholm S, et al. T-Cell Levels Are Prognostic in Mantle Cell Lymphoma. Clin Cancer Res. 2014;20(23):6096–6104. https://doi.org/10.1158/1078-0432.CCR-14-0889Nygren L, Wasik AM, Baumgartner-Wennerholm S, et al. T-Cell Levels Are Prognostic in Mantle Cell Lymphoma. Clin Cancer Res. 2014;20(23):6096–6104. https://doi.org/10.1158/1078-0432.CCR-14-0889Alonso-Álvarez S, Vidriales MB, Caballero MD, et al. The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy. Leuk Lymphoma. 2017;58(5):1144–1152. https://doi.org/10.1080/10428194.2016.1239263Alonso-Álvarez S, Vidriales MB, Caballero MD, et al. The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy. Leuk Lymphoma. 2017;58(5):1144–1152. https://doi.org/10.1080/10428194.2016.1239263Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res. 2015;75(11):2139–2145. https://doi.org/10.1158/0008-5472.CAN-15-0255Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res. 2015;75(11):2139–2145. https://doi.org/10.1158/0008-5472.CAN-15-0255Strickler JH, Hanks BA, Khasraw M. Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better? Clin Cancer Res. 2021;27(5):1236–1241. https://doi.org/10.1158/1078-0432.CCR-20-3054Strickler JH, Hanks BA, Khasraw M. Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better? Clin Cancer Res. 2021;27(5):1236–1241. https://doi.org/10.1158/1078-0432.CCR-20-3054Wienand K, Chapuy B, Stewart C, et al. Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. Blood Adv. 2019;3(23):4065–4080. https://doi.org/10.1182/bloodadvances.2019001012Wienand K, Chapuy B, Stewart C, et al. Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. Blood Adv. 2019;3(23):4065–4080. https://doi.org/10.1182/bloodadvances.2019001012Chapuy B, Stewart C, Dunford AJ, et al. Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade. Blood. 2019;134(26):2369–2382. https://doi.org/10.1182/blood.2019002067Chapuy B, Stewart C, Dunford AJ, et al. Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade. Blood. 2019;134(26):2369–2382. https://doi.org/10.1182/blood.2019002067Tian T, Li J, Xue T, et al. Microsatellite instability and its associations with the clinicopathologic characteristics of diffuse large B-cell lymphoma. Cancer Med. 2020;9(7):2330–2342. https://doi.org/10.1002/cam4.2870Tian T, Li J, Xue T, et al. Microsatellite instability and its associations with the clinicopathologic characteristics of diffuse large B-cell lymphoma. Cancer Med. 2020;9(7):2330–2342. https://doi.org/10.1002/cam4.2870El Hussein S, Daver N, Liu JL, et al. Microsatellite Instability Assessment by Immunohistochemistry in Acute Myeloid Leukemia: A Reappraisal and Review of the Literature. Clin Lymphoma Myeloma Leuk. 2022;22(6):e386–e391. https://doi.org/10.1016/j.clml.2021.12.004El Hussein S, Daver N, Liu JL, et al. Microsatellite Instability Assessment by Immunohistochemistry in Acute Myeloid Leukemia: A Reappraisal and Review of the Literature. Clin Lymphoma Myeloma Leuk. 2022;22(6):e386–e391. https://doi.org/10.1016/j.clml.2021.12.004Chen R, Zinzani PL, Fanale MA, et al. KEYNOTE-087. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J Clin Oncol. 2017;35(19):2125–2132. https://doi.org/10.1200/JCO.2016.72.1316Chen R, Zinzani PL, Fanale MA, et al. KEYNOTE-087. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J Clin Oncol. 2017;35(19):2125–2132. https://doi.org/10.1200/JCO.2016.72.1316Armand P, Rodig S, Melnichenko V, et al. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. J Clin Oncol. 2019;37(34):3291–3299. https://doi.org/10.1200/JCO.19.01389Armand P, Rodig S, Melnichenko V, et al. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. J Clin Oncol. 2019;37(34):3291–3299. https://doi.org/10.1200/JCO.19.01389Geoerger B, Kang HJ, Yalon-Oren M, et al. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): Interim analysis of an open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2020;21(1):121–133. https://doi.org/10.1016/S1470-2045(19)30671-0Geoerger B, Kang HJ, Yalon-Oren M, et al. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): Interim analysis of an open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2020;21(1):121–133. https://doi.org/10.1016/S1470-2045(19)30671-0Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311–319. https://doi.org/10.1056/247NEJMoa1411087Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311–319. https://doi.org/10.1056/247NEJMoa1411087Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. J Clin Oncol. 2016;34(23):2698–2704. https://doi.org/10.1200/JCO.2015.65.9789Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. J Clin Oncol. 2016;34(23):2698–2704. https://doi.org/10.1200/JCO.2015.65.9789Park JA, Cheung NV. Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies. Cancer Treat Rev. 2017;58:22–33. https://doi.org/10.1016/j.ctrv.2017.05.006Park JA, Cheung NV. Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies. Cancer Treat Rev. 2017;58:22–33. https://doi.org/10.1016/j.ctrv.2017.05.006Harker-Murray P, Mauz-Körholz C, Leblanc T, et al. Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults. Blood. 2023;141(17):2075–2084. https://doi.org/10.1182/blood.2022017118Harker-Murray P, Mauz-Körholz C, Leblanc T, et al. Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults. Blood. 2023;141(17):2075–2084. https://doi.org/10.1182/blood.2022017118Shi Y. Landscape of the clinical development of China innovative anti-lung cancer drugs. Cancer Pathog Ther. 2022;1(1):67–75. doi:https://doi.org/10.1016/j.cpt.2022.10.003Shi Y. Landscape of the clinical development of China innovative anti-lung cancer drugs. Cancer Pathog Ther. 2022;1(1):67–75. doi:https://doi.org/10.1016/j.cpt.2022.10.003Markham A, Keam SJ. Camrelizumab: First Global Approval. Drugs. 2019;79(12):1355–1361. https://doi.org/10.1007/s40265-019-01167-0Markham A, Keam SJ. Camrelizumab: First Global Approval. Drugs. 2019;79(12):1355–1361. https://doi.org/10.1007/s40265-019-01167-0Tao R, Fan L, Song Y, et al. Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4) Signal Transduct. Target Ther. 2021;6(1):365. https://doi.org/10.1038/s41392-021-00768-0Tao R, Fan L, Song Y, et al. Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4) Signal Transduct. Target Ther. 2021;6(1):365. https://doi.org/10.1038/s41392-021-00768-0Que Y, Wang J, Sun F, et al. Safety and clinical efficacy of sintilimab (anti-PD-1) in pediatric patients with advanced or recurrent malignancies in a phase I study. Signal Transduct Target Ther. 2023;8(1):392. https://doi.org/10.1038/s41392-023-01636-9Que Y, Wang J, Sun F, et al. Safety and clinical efficacy of sintilimab (anti-PD-1) in pediatric patients with advanced or recurrent malignancies in a phase I study. Signal Transduct Target Ther. 2023;8(1):392. https://doi.org/10.1038/s41392-023-01636-9Kim SJ, Lim JQ, Laurensia Y, et al. Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: An open-label phase 2 study. Blood. 2020;136(24):2754–2763. https://doi.org/10.1182/blood.2020007247Kim SJ, Lim JQ, Laurensia Y, et al. Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: An open-label phase 2 study. Blood. 2020;136(24):2754–2763. https://doi.org/10.1182/blood.2020007247Herrera AF, Goy A, Mehta A, et al. Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma. Am J Hematol. 2020;95(1):18–27. https://doi.org/10.1002/ajh.25659Herrera AF, Goy A, Mehta A, et al. Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma. Am J Hematol. 2020;95(1):18–27. https://doi.org/10.1002/ajh.25659Geoerger B, Zwaan CM, Marshall LV, et al. Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): A multicentre phase 1-2 study. Lancet Oncol. 2020;21(1):134–144. https://doi.org/10.1016/S1470-2045(19)30693-XGeoerger B, Zwaan CM, Marshall LV, et al. Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): A multicentre phase 1-2 study. Lancet Oncol. 2020;21(1):134–144. https://doi.org/10.1016/S1470-2045(19)30693-XOnesti CE, Frères P, Jerusalem G. Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients’ treatment. J Thorac Dis. 2019;11(1):35–38. https://doi.org/10.21037/jtd.2018.12.47Onesti CE, Frères P, Jerusalem G. Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients’ treatment. J Thorac Dis. 2019;11(1):35–38. https://doi.org/10.21037/jtd.2018.12.47Cheson BD, Ansell S, Schwartz L, et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016;128(21):2489–2496. https://doi.org/10.1182/blood-2016-05-718528Cheson BD, Ansell S, Schwartz L, et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016;128(21):2489–2496. https://doi.org/10.1182/blood-2016-05-718528Lee AJ, Kim KW, Cho YC, et al. Incidence of Immune-Mediated Pseudoprogression of Lymphoma Treated with Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis. J Clin Med. 2021;10(11):2257. https://doi.org/10.3390/jcm10112257Lee AJ, Kim KW, Cho YC, et al. Incidence of Immune-Mediated Pseudoprogression of Lymphoma Treated with Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis. J Clin Med. 2021;10(11):2257. https://doi.org/10.3390/jcm10112257

The authors declare that there are no conflicts of interest present.